Raising $279 million in an IPO and another $25 million in a concurrent private placement, Odyssey Therapeutics Inc. is advancing its lead phase II asset, OD-001, in ulcerative colitis, with plans to bring its SLC15A4 program into the clinic for lupus.
Climb Bio Inc. outlined May 5 an enticing data spill ahead this year with Fc-enhanced monoclonal antibody budoprutug (budo) in autoimmune diseases. Mizuho analyst Joseph Catanzaro appreciated in his report Wellesley Hills, Mass.-based Climb’s “conviction that CD19 represents a best-in-class pan-B-cell depletion target across antibody-mediated autoimmune diseases – a relative white space for conventional mAbs.”
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Artera, Bridgebio, Diakonos, Norgine, Nuvation.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Acea, Biontech, Boehringer Ingelheim, Deuteroncology, Eli Lilly, Epik, Halozyme, Lucent Diagnostics, Lunai Bioworks, Mannkind, Oncotelic, Oruka, Pathos AI, Phoenix Asia, Ribocure, Scilex Holding, Suzhou Ribo Life, Tempus AI, United Therapeutics.
Clinical updates for biopharma and med tech, including data readouts and publications: Aptevo, Atossa, Avalo, Bioxodes, Braintree, Cairn Surgical, Eupraxia, Helio Genomics, Hoth, Lytix, Medicus, Mingmed, Spago, Verrica.
New hires and promotions in the biopharma and med-tech industries, including: Abli, Actuate, Anavex, Cellprothera, Cristcot, Cytora, Immutrin, Turbett Surgical.
Atara Biotherapeutics Inc.’s allogeneic T-cell immunotherapy, Ebvallo (tabelecleucel), for Epstein-Barr virus-positive post-transplant lymphoproliferative disease isn’t out of the running yet. Despite grim predictions in the wake of the U.S. FDA’s second complete response letter for the drug in January, Atara and partner Pierre Fabre Pharmaceuticals Inc. reached agreement with the regulator on a path for resubmitting the BLA.
Infectious disease-focused biopharma stocks, tracked on the BioWorld Infectious Disease Index (BIDI), saw their collective shares roughly follow the path of broader markets like the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial Average (DJIA) in early 2026. The BIDI ended April up 3.8%, followed by the DJIA with a 3.31% gain and 2.73% for the NBI, following a similar pattern to 2025.
RSS
